UPDATE: The Cincinnati Marriot at RiverCenter and the Embassy Suites Cincinnati Rivercenter are SOLD OUT.

Cincinnati Marriott at RiverCenter
10 West RiverCenter Blvd
Covington, KY 41011

FOR RESERVATIONS:

CLICK HERE or call (859) 261-2900.

Hotel room rates are $149.00 per night for a Single or Double Room. Hotel room rates are subject to applicable state and local taxes in effect at the time of check-out.

When booking your hotel room, keep in mind conference activities run from Thursday evening through Sunday morning. As such, you may wish to arrive on Thursday, November 9, and depart on Sunday, November 12.

You can call the Marriott directly to make your reservations at (859) 261-2900. Be sure to mention you will be attending the “RLDC · 2018 and LAMposium” to qualify for the discounted room rate of $149.00 per night..

To receive this discounted room rate, you must make your reservation before 11:59 PM ET, Monday, August 13, 2018.

If you will need supplemental oxygen during your visit, please pre-order through your regular oxygen supplier and make sure your oxygen is delivered to the front desk of the Marriott with your name on the order.

The LAM Foundation is extremely grateful to all Sponsors who make the Breath of Hope Gala possible. If you would like to sponsor a table for 10, click here. For more information, please download this form or contact Katie Jensen at kjensen@thelamfoundation.org.

Ed Plocharczyk (in memory of Jean Togikawa)

Ann & Jack Struthers

John Adler (in memory of Vi Adler)

Michael Murphy (in memory of Coleen Murphy)

Dawn & Bob Haugom

Sarah Morgan

Chuck Wehland

For more information about sponsorship options available, click the link below or contact Katie Jensen at KJENSEN@THELAMFOUNDATION.ORG.

The LAM Foundation could not host this event without the help of our incredible Gala Steering Committee. Thank you to the following women who have made this event possible:

Mindy Bartlett
Maja Flannery
Grace Hamilton
Dawn Haugom
Lindsay Henry
Jenny Jostworth
Kristin Kerwin
Christine Kruger
Shannon McDaniel-Myers
Brittany Runyon
Marna Wende

Please contact Katie Jensen at kjensen@thelamfoundation.org if you are interested in volunteering at the Gala.

Lymphangioleiomyomatosis (LAM) is a rare lung disease that occurs almost exclusively in women. There is no cure. More than 2,000 women with LAM have been identified to date, but it is suspected that there may be as many as 250,000 undiagnosed or misdiagnosed patients living with LAM worldwide. The average age of women at the time of diagnosis is approximately 35 years old, though most women with LAM have symptoms for several years before ultimately being diagnosed.

LAM is characterized by an abnormal growth of smooth muscle cells, especially in the lungs, lymphatic system and kidneys. Unregulated growth of these cells can lead to loss of lung function, accumulation of lymph rich-fluid in the chest and abdomen and growth of tumors in the kidneys. Leading researchers believe that LAM may be the simplest form of cancer.

Treatment with sirolimus (rapamycin or Rapamune) or everolimus (Afinitor) has been proven to stabilize lung function in some women with LAM. While many women with LAM add several years to their lives through pharmacotherapy, oxygen therapy, or lung transplantation, there is no cure for this fatal disease.

To learn more about LAM, please click here.

The LAM Foundation is the global leader in the fight against lymphangioleiomyomatosis (LAM), offering support to all women living with LAM, their families and friends, and physicians and researchers worldwide. The LAM Foundation urgently seeks safe and effective treatments, and ultimately a cure, for lymphangioleiomyomatosis (LAM) through advocacy and the funding of promising research. We are dedicated to serving the scientific, medical and patient communities by offering information, resources and a worldwide network of hope and support.

Founded in 1995 as a grass roots effort in Cincinnati, OH, The LAM Foundation has evolved into an organization that is described by the National Heart, Lung and Blood Institute (NHLBI) as "a model for voluntary health agencies."

The LAM Foundation has raised and invested more than $25 million in research over the last 23 years, resulting in the fundamental understanding of the genetic cause of LAM which led to the first ever clinical treatment trial and ultimately an FDA approved treatment for the disease. Sirolimus was approved in 2015 after a strikingly collaborative global effort led by The LAM Foundation and a team of dedicated scientists, researchers, clinicians, industry and government health agencies. The LAM Foundation also funded pivotal research that advanced knowledge of the mTOR pathway (important in regulating the cell division cycle), which has proven central to understanding other, much more common diseases such as cancer, diabetes and obesity. Great opportunities exist for The LAM Foundation to serve as a model for other rare disease organizations, and to share knowledge to propel treatments and cures in rare and common diseases, potentially affecting millions.

To learn more about The LAM Foundation, please click here.